Drug facts
MoleculeCelecoxib (Celebrex)
Generics already compete: 18 makers on the market. 67 A-rated products from 18 makers substitute at the counter.
Celebrex was first approved by the FDA on 12/31/1998 under NDA 020998; the application holder is Upjohn US 2 LLC.
The latest NADAC for CELECOXIB 200 MG CAPSULE is $0.07 per unit (as of 10/28/2026).
Holder Upjohn US 2 LLCApplication NDA 020998Approved 12/31/1998
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Celebrex patent listed in the Orange Book Orange Book
- Later patents, other products
- Vyscoxa 09/17/2045; Elyxyb 05/27/2036 Orange Book
02Competition
- Generics
- 18 generic makers Orange Book
- First generic approved
- 05/30/2014 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Celecoxib profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.07 per unitCELECOXIB 200 MG CAPSULE, mid-priced of 4 strengths, as of 10/28/2026 CMS NADAC
- Latest recall
- 05/13/2025Class II, Celecoxib, Avkare FDA enforcement
04Product
- Application holder
- Upjohn US 2 LLC Orange Book
- Application
- NDA 020998 Orange Book
- First approved
- 12/31/1998 Orange Book
- Dosage forms
- capsule; solution; suspension
- Routes
- oral
- Other brand names
- ElyxybVyscoxa
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.